| Cardiac Fibrosis and Remodeling | Lifetime | 3 | JP 1 | 99.83 |
| Signaling Pathways in Disease | Lifetime | 11 | JP 1 | 99.66 |
| Congenital heart defects research | Lifetime | 30 | JP 1 | 99.53 |
| Cardiomyopathy and Myosin Studies | Lifetime | 63 | JP 2 | 99.47 |
| Cardiovascular Function and Risk Factors | Lifetime | 542 | JP 7 | 99.03 |
| Renin-Angiotensin System Studies | Lifetime | 130 | JP 13 | 98.38 |
| Receptor Mechanisms and Signaling | Lifetime | 633 | JP 22 | 98.48 |
| Cardiac Ischemia and Reperfusion | Lifetime | 284 | JP 17 | 98.08 |
| Heart Failure Treatment and Management | Lifetime | 425 | JP 14 | 98.43 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 804 | JP 32 | 98.16 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 169 | JP 1 | 96.18 |
| Cardiovascular Disease and Adiposity | Lifetime | 795 | JP 30 | 96.30 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 581 | JP 34 | 96.48 |
| Tissue Engineering and Regenerative Medicine | Lifetime | 820 | JP 38 | 96.08 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 869 | JP 43 | 96.29 |
| Heat shock proteins research | Lifetime | 453 | JP 34 | 95.47 |
| Connective tissue disorders research | Lifetime | 470 | JP 17 | 95.20 |
| Protein Kinase Regulation and GTPase Signaling | Lifetime | 847 | JP 76 | 94.90 |
| Telomeres, Telomerase, and Senescence | Lifetime | 445 | JP 29 | 93.48 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 958 | JP 52 | 93.17 |
| ATP Synthase and ATPases Research | Lifetime | 843 | JP 69 | 92.88 |
| Kawasaki Disease and Coronary Complications | Lifetime | 984 | JP 208 | 84.82 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 360 | JP 14 | 97.48 |
| Diabetes Treatment and Management | 2021-2025 | 396 | JP 11 | 95.75 |
| Cardiac Health and Mental Health | 2021-2025 | 272 | JP 8 | 92.21 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 372 | JP 15 | 92.81 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 151 | JP 4 | 90.57 |
| Heart Failure Treatment and Management | 2021-2025 | 613 | JP 47 | 92.86 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 603 | JP 28 | 91.76 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 268 | JP 6 | 90.04 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 473 | JP 11 | 90.59 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 546 | JP 30 | 86.66 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 581 | JP 35 | 85.64 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 236 | JP 11 | 82.97 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 707 | JP 40 | 84.79 |
| Hormonal Regulation and Hypertension | 2021-2025 | 637 | JP 56 | 84.26 |
| Connective tissue disorders research | 2021-2025 | 282 | JP 22 | 81.29 |
| Cardiomyopathy and Myosin Studies | 2021-2025 | 923 | JP 20 | 83.72 |
| Congenital heart defects research | 2021-2025 | 581 | JP 21 | 78.04 |
| Potassium and Related Disorders | 2021-2025 | 370 | JP 29 | 73.32 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 406 | JP 29 | 63.77 |
| Signaling Pathways in Disease | 2021-2025 | 501 | JP 24 | 60.33 |
| GDF15 and Related Biomarkers | 2021-2025 | 739 | JP 30 | 49.14 |
| Nuclear Structure and Function | 2021-2025 | 896 | JP 46 | 49.10 |